U.S. Authorities Approve Review for Deruxtecan-Datopotamab Treatment Submission for Earlier Managed Advanced Non-Squamous NSCLC Cases.

Almirall gains rights to develop Novo Nordisk’s anti-IL-21 antibody for dermatologic applications as a pioneering treatment.

Citius Pharma re-submits its LYMPHIR™ BLA, comprising Denileukin Diftitox, aiming to treat relapsed/refractory Cutaneous T-Cell Lymphoma in adults.

Kurome Therapeutics has received authorization from the FDA to conduct clinical trials for KME-0584, aimed at addressing Acute Myeloid Leukemia (AML) and advanced-stage Myelodysplastic Syndromes (MDS).

Acousia Therapeutics disclosed that it has initiated participant enrollment for its second stage PROHEAR trial.

Curadev proudly launches CRD3874, an innovative allosteric small molecule that uniquely activates the STING pathway without targeting the cGAMP site.

Repare Therapeutics Inc. announced the first patient has been treated in their LIONS Phase 1 trial, focusing on RP-1664 – a leading oral inhibitor targeting polo-like kinase 4, intended for solo therapy.

Nuvig Therapeutics, Inc., initiates first human trial of NVG-2089 for treating inflammatory myopathies and severe autoimmune skin diseases.

Atara Biotherapeutics Reports Filing a New Drug Application for ATA3219 Aimed at Treating Lupus Kidney Inflammation.

CalciMedica has received approval from the FDA to proceed with a Phase 2 study of Auxora™ in treating severe cases of acute kidney injury.

Artax has initiated the dosing of the inaugural participant in their Phase 2a clinical study for Psoriasis, assessing the effects of compound AX-158.

Otsuka Reveals Key Outcomes from Final Stage Trial of AVP-786 for Managing Alzheimer’s-Related Dementia Agitation.